BAY 94-8662 shows promise in HF patients with reduced renal function.

BAY 94-8662 - a next generation mineralocorticoid receptor antagonist (MRA) - is at least as effective as spironolactone in reducing biomarkers of hemodynamic stress, and associated with a lower incidence of hyperkalaemia and worsening renal function (WRF), reported the phase II ARTs study. Read more Topics: Heart Failure (HF)
Source: ESC News and Press - Category: Cardiology Source Type: news